Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
September 22 2022 - 7:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced multiple presentations at
the American Academy of Ophthalmology (AAO) 2022 Annual Meeting
being held September 30 - October 3, 2022 at McCormick Place
Convention Center in Chicago, IL.
“We have a big presence at AAO this year with many presentations
discussing product candidates across multiple ophthalmic
indications, with an emphasis on retina,” said Rabia Gurses Ozden,
MD, Chief Medical Officer of Ocular Therapeutix. “Most notably, we
anticipate presenting 28-week data from our U.S. Phase 1 trial of
OTX-TKI for the treatment of Wet AMD in a late breaker session on
Friday afternoon. We will also be making two ePoster presentations
on the OTX-TKI program as well as sharing real-world data updates
on DEXTENZA.”
Eyecelerator @ AAO 2022 Retina Showcase Presentation:
- Session Title: Presenting Company Showcase: Retina,
Therapeutics, and Technology + Devices Presentation
Date/Times: Thursday, September 29, 2022, 2:00 – 2:05 PM CDT
Location: McCormick Place Convention Center Presentation
type: Podium Presentation Presenter: Peter K. Kaiser,
MD
Retina Subspecialty Day Presentation:
- Title: Interim Safety and Efficacy Data from a Phase 1
Clinical Trial of Sustained-release Axitinib Hydrogel Implant
(OTX-TKI) in Wet AMD Subjects Session Title: Late Breaking
Developments, Part I (RET09) Presentation Date/Times:
Friday, September 30, 2022, 3:29-3:34 PM CDT Location: Arie
Crown Presentation type: Podium Presentation
Presenter: Dilsher S. Dhoot, MD
Poster Theater Presentation:
- Title: Real-World Safety Analysis of an Intracanalicular
Dexamethasone Insert Using the Academy's IRIS® Registry Session
Title: Cataract (PT01) Presentation Date/Times:
Saturday, October 1, 2022, 9:40-9:50 AM CDT Location: Hall A
Poster Theater and Lounge Presentation type: Poster Theatre
Presenter: Robert T. Chang, MD
ePosters:
- Title: Real-World Patient Demographics and Clinical
Characteristics of an Intracanalicular Dexamethasone Insert Using
the Academy’s IRIS® Registry Session Title: Cataract
Viewing Date/Times: Tuesday, September 27, 2022 starting at
9:00 AM CDT Presentation type: ePoster (PO021)
Presenter: Michael Mbagwu, MD
- Title: Interim 28-weeks Data from a Phase 1 US Study of
Sustained-release Axitinib Hydrogel Implant (OTX-TKI) in Previously
Treated Wet AMD Subjects Session Title: Retina, Vitreous
Viewing Date/Times: Friday, September 30, 2022 starting at
5:00 PM CDT Presentation type: ePoster (PO359)
Presenter: Arshad M. Khanani, MD
- Title: Australia-based Phase 1 Trial of a Novel,
Hydrogel-based, Intravitreal Axitinib Implant for the Treatment of
Neovascular Age-related Macular Degeneration Session Title:
Retina, Vitreous Viewing Date/Times: Friday, September 30,
2022 starting at 5:00 PM CDT Presentation type: ePoster
(PO360) Presenter: Andrew A. Moshfeghi, MD
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc.
is a biopharmaceutical company focused on the formulation,
development, and commercialization of innovative therapies for
diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s first commercial drug product, DEXTENZA®, is an
FDA-approved corticosteroid for the treatment of ocular
inflammation and pain following ophthalmic surgery and ocular
itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: OTX-TKI
(axitinib intravitreal implant), currently in Phase 1 clinical
trials for the treatment of wet AMD and other retinal diseases;
OTX-TIC (travoprost intracameral implant), currently in a Phase 2
clinical trial for the treatment of primary open-angle glaucoma or
ocular hypertension; and OTX-CSI (cyclosporine intracanalicular
insert) for the chronic treatment of dry eye disease and OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease, both of
which have completed Phase 2 clinical trials.
Forward Looking Statements Any statements in this press
release about future expectations, plans, and prospects for the
Company, including the commercialization of DEXTENZA®, ReSure®
Sealant, or any of the Company’s product candidates; the
development and regulatory status of the Company’s product
candidates, such as the Company’s development of and prospects for
approvability of OTX-TIC for the treatment of primary open-angle
glaucoma or ocular hypertension, OTX-TKI for the treatment of
retinal diseases including wet AMD, OTX-DED for the short-term
treatment of the signs and symptoms of dry eye disease, and OTX-CSI
for the chronic treatment of dry eye disease; the Company’s plans
to advance the development of its product candidates or preclinical
programs; the ongoing development of the Company’s
extended-delivery hydrogel depot technology; the potential utility
of any of the Company’s product candidates; the size of potential
markets for the Company’s product candidates; the potential
benefits and future operations of Company collaborations, including
any potential future costs or payments thereunder; projected net
product revenue, in-market sales and other financial and
operational metrics of DEXTENZA and ReSure Sealant; the sufficiency
of the Company’s cash resources; the Company’s anticipated
participation in future presentations and medical conferences; and
other statements containing the words "anticipate," "believe,"
"estimate," "expect," "intend", "goal," "may", "might," "plan,"
"predict," "project," "target," "potential," "will," "would,"
"could," "should," "continue," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors. Such forward-looking
statements involve substantial risks and uncertainties that could
cause the Company’s preclinical and clinical development programs,
future results, performance or achievements to differ significantly
from those expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the timing and
costs involved in commercializing DEXTENZA, ReSure Sealant or any
product candidate that receives regulatory approval, including the
conduct of post-approval studies, the ability to successfully
develop and commercialize products for the ophthalmology office
setting, the ability to retain regulatory approval of DEXTENZA,
ReSure Sealant or any product candidate that receives regulatory
approval, the ability to maintain and the sufficiency of product,
procedure and any other reimbursement codes for DEXTENZA, the
initiation, timing, conduct and outcomes of clinical trials,
whether clinical trial data such as the data reported in this
release will be indicative of the results of subsequent clinical
trials, availability of data from clinical trials and expectations
for regulatory submissions and approvals, the Company’s ability to
enter into and perform its obligations under collaborations and the
performance of its collaborators under such collaborations, the
Company’s scientific approach and general development progress, the
availability or commercial potential of the Company’s product
candidates, the Company’s ability to meet supply demands, the
Company’s ability to generate its projected net product revenue and
in-market sales on the timeline expected, if at all, the
sufficiency of cash resources, the Company’s existing indebtedness,
the ability of the Company’s creditors to accelerate the maturity
of such indebtedness upon the occurrence of certain events of
default, the severity and duration of the COVID-19 pandemic
including its effect on the Company’s revenues and relevant
regulatory authorities’ operations, any additional financing needs,
the Company’s ability to recruit and retain key personnel, and
other factors discussed in the “Risk Factors” section contained in
the Company’s quarterly and annual reports on file with the
Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
the Company’s views as of the date of this press release. The
Company anticipates that subsequent events and developments will
cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in
the future, the Company specifically disclaims any obligation to do
so, whether as a result of new information, future events or
otherwise, except as required by law. These forward-looking
statements should not be relied upon as representing the Company’s
views as of any date subsequent to the date of this press
release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220922005225/en/
Investors Ocular Therapeutix Donald Notman Chief
Financial Officer dnotman@ocutx.com
or
Westwicke, an ICR Company Chris Brinzey, 339-970-2843 Managing
Director chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice
President, Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2023 to Apr 2024